rcs-01
Cell therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2015 (NCT02391935)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- FibroblastSupplementation
Fibroblast supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rcs-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02391935 | Phase 1 | Oct 10, 2015 | Datinf GmbH, Innovacell Biotechnologie AG, JensonR+ Limited, RepliCel Life Sciences, Inc., Syreon Corporation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Datinf GmbH | For profit | 1 | 0 | 1 | 2015 |
| Innovacell Biotechnologie AG | For profit | 1 | 0 | 1 | 2015 |
| JensonR+ Limited | For profit | 1 | 0 | 1 | 2015 |
| RepliCel Life Sciences, Inc. | For profit | 1 | 1 | 1 | 2015 |
| Syreon Corporation | For profit | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1